Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Large-scale testing (Phase 3)Not Yet RecruitingNCT07440290What this trial is testingDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.Who this might be right forHaematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+16 more Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT01116271What this trial is testingStudy of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With ColorecWho this might be right forColorectal Cancer AstraZeneca 32
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052What this trial is testingStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer (DTC) Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Ended earlyNCT04534283What this trial is testingA Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.Who this might be right forCancerCancer MetastaticBRAF V600E+4 more Anita Turk 16
Testing effectiveness (Phase 2)Ended earlyNCT04985604What this trial is testingTovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsWho this might be right forMelanomaSolid TumorCRAF Gene Amplification+20 more Day One Biopharmaceuticals, Inc. 23
Testing effectiveness (Phase 2)Study completedNCT04620330What this trial is testingAvutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerWho this might be right forNon Small Cell Lung CancerKRAS Activating Mutation Verastem, Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT05786924What this trial is testingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesWho this might be right forNon-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT01086267What this trial is testingSafety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal CancerWho this might be right forColorectal Cancer Bristol-Myers Squibb 17
Early research (Phase 1)Ended earlyNCT07121829What this trial is testingTovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsWho this might be right forMelanomaSolid TumorPilocytic Astrocytoma+7 more Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT01781026What this trial is testingPhase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain MetastasesWho this might be right forMelanoma Yale University 2
Early research (Phase 1)Ended earlyNCT04249843What this trial is testingStudy of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory TumorsWho this might be right forSolid TumorB-Raf Mutation-Related Tumors MapKure, LLC 109
Not applicableStudy completedNCT01720758What this trial is testingAssessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative DiseaseWho this might be right forHairy Cell LeukemiaSplenic Marginal Zone Lymphoma HaEmek Medical Center, Israel 20
Early research (Phase 1)Active Not RecruitingNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Early research (Phase 1)Ended earlyNCT06270082What this trial is testingStudy of IK-595 in RAS- or RAF-altered Advanced TumorsWho this might be right forSolid Tumor, AdultColorectal CancerPancreatic Cancer+7 more Ikena Oncology 75
Not applicableApproved For MarketingNCT05760586What this trial is testingExpanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade GliomaWho this might be right forLow-grade Glioma Day One Biopharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT01514864What this trial is testingTrial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationWho this might be right forCarcinoma, Non-small Cell Lung Bristol-Myers Squibb 19
Early research (Phase 1)Looking for participantsNCT06299839What this trial is testingPAS-004 in Patients With Advanced Solid TumorsWho this might be right forRAS MutationNF1 MutationRAF Mutation+1 more Pasithea Therapeutics Corp. 48
Early research (Phase 1)Looking for participantsNCT06104488What this trial is testingAvutometinib for People With Solid Tumor CancersWho this might be right forRefractory CancerCNS TumorsCNS Tumor, Adult+12 more Memorial Sloan Kettering Cancer Center 23
Early research (Phase 1)Study completedNCT01436656What this trial is testingA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaWho this might be right forMelanoma and Metastatic Colorectal Cancer Pfizer 107